How to Get Alprostadil (Caverject/MUSE) in Maine

What Is Alprostadil and Why Is It Prescribed for Erectile Dysfunction?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpus cavernosum, increases arterial inflow, and produces an erection within 5 to 20 minutes of administration. It is the first-line injectable option for men who do not respond to oral phosphodiesterase type-5 (PDE5) inhibitors such as sildenafil or tadalafil. Caverject is delivered by direct intracavernosal injection, while MUSE (Medicated Urethral System for Erection) delivers an alprostadil pellet into the urethra via a small applicator.

The key randomized controlled trial by Linet et al. (N=296), published in the New England Journal of Medicine in 1996, found that 94.4% of injection attempts with alprostadil resulted in an erection sufficient for intercourse, compared with 13.7% of placebo attempts (P<0.001) [1]. That single study established the drug's clinical profile for the next three decades. A separate multicenter trial of intraurethral alprostadil showed that 64.9% of men who responded to the drug in the clinic also achieved intercourse at home at least once [2].

The FDA approved Caverject Impulse (alprostadil for injection) under NDA 019977, and MUSE under NDA 020484 [3]. Both remain prescription-only products, meaning a licensed prescriber must authorize every dispensing event in Maine.

Learn more about the pharmacology of alprostadil on PubMed

Who Can Prescribe Alprostadil in Maine?

Maine law grants full independent prescribing authority to physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). All three can legally write a prescription for alprostadil without a supervising physician co-signature, provided they hold an active Maine controlled-substance registration where applicable and a valid Drug Enforcement Administration (DEA) registration if the treatment plan includes controlled substances. Alprostadil itself is not a DEA-scheduled substance, so an NP or PA can prescribe it under their standard state license alone [4].

Urologists are the most common prescribers because they can also perform the in-office test dose that confirms correct injection technique and rules out priapism risk. Primary care physicians, internal medicine specialists, and endocrinologists also prescribe alprostadil regularly for men whose erectile dysfunction has a clear vascular or hormonal etiology. According to the American Urological Association's 2018 erectile dysfunction guideline, "intracavernosal pharmacotherapy is an appropriate second-line therapy for patients who have failed or are not candidates for PDE5 inhibitor therapy" [5].

Telehealth prescribers who hold an active Maine license and have established a valid patient-provider relationship through a synchronous video consultation are equally permitted to prescribe alprostadil under Maine Revised Statutes Title 32, which governs professional licensing and telehealth practice [6].

How Telehealth Prescribing Works in Maine for Alprostadil

Maine has authorized telehealth prescribing since the state updated its telehealth standards in 2019. A prescriber licensed in Maine may conduct a synchronous video visit, review relevant history and prior treatment records, and issue an alprostadil prescription without the patient ever entering a clinic. The prescription then routes to either a retail pharmacy or a 503A compounding pharmacy.

The visit typically covers four areas. First, the prescriber reviews prior PDE5 inhibitor use and confirms treatment-refractory status. Second, they screen for contraindications, including conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia), anatomical deformity of the penis, or concurrent use of anticoagulants that would raise injection-site bleeding risk [7]. Third, they order or review baseline labs. Fourth, they discuss the two delivery formats, intracavernosal injection versus intraurethral suppository, and confirm the patient can self-administer safely.

The FDA's prescribing information for Caverject specifies that "the first dose of Caverject Impulse should be given under medical supervision with appropriate monitoring," meaning an in-clinic or supervised first dose is the standard-of-care benchmark even when the prescription itself is issued via telehealth [3]. Some Maine telehealth providers satisfy this requirement by coordinating a single in-person first-dose session with a local urology clinic or by using a detailed video-guided injection training protocol.

Review the FDA's complete prescribing information for Caverject

Labs and Medical History Required Before Starting Alprostadil in Maine

A focused but meaningful workup helps the prescriber identify the underlying cause of erectile dysfunction and screen for contraindications. The standard pre-treatment checklist for alprostadil in Maine mirrors the AUA erectile dysfunction guideline's recommended evaluation [5].

Required or strongly recommended labs:

Blood pressure and heart rate (measured at visit), fasting glucose or HbA1c, total testosterone (morning draw, 8 to 10 a.m.), complete blood count (to screen for hematologic conditions linked to priapism), and lipid panel [5][8]. A PSA test is added if the patient is over 40 and has not had one within 12 months, particularly if concurrent testosterone therapy is planned.

The testosterone draw matters because hypogonadism is a reversible contributor to erectile dysfunction in approximately 30% of men with the condition, and treating low testosterone with testosterone replacement therapy (TRT) may reduce or eliminate the need for alprostadil altogether [8]. Correcting testosterone first is a reasonable clinical step before committing to injection therapy.

Coagulation studies are added when the patient uses warfarin, a direct oral anticoagulant, or has known coagulopathy. Patients with a history of priapism require a sickle cell screen if not previously documented [7].

Medical history items the prescriber will review:

Prior urologic surgeries (radical prostatectomy, penile implant history), pelvic radiation, neurologic conditions (multiple sclerosis, spinal cord injury), cardiovascular disease severity (New York Heart Association class), and a complete medication list to flag interactions with vasoactive drugs or anticoagulants.

See the AUA erectile dysfunction clinical guideline

Step-by-Step: Getting an Alprostadil Prescription in Maine

The process from first inquiry to first injection typically spans five to seven business days when using a telehealth pathway.

Step 1. Complete an online intake form. Most telehealth platforms collect chief complaint, medication list, allergy history, prior ED treatment history, and relevant labs before the video visit. Uploading recent lab results can shorten the visit.

Step 2. Attend a synchronous video consultation. The prescriber conducts a focused history, reviews labs, discusses delivery format preferences, and answers patient questions. The visit usually runs 20 to 30 minutes. Under Maine telehealth law, this synchronous encounter is sufficient to establish the patient-provider relationship needed for prescribing [6].

Step 3. Receive the prescription. If alprostadil is clinically appropriate, the prescriber sends an electronic prescription to the patient's chosen pharmacy. For brand-name Caverject at retail pharmacies, the prescription routes to a chain or independent Maine pharmacy. For compounded alprostadil, it routes to a 503A compounding pharmacy licensed in Maine.

Step 4. Arrange first-dose training. Brand Caverject kits include a detailed instruction guide. Many telehealth providers schedule a follow-up video call to walk through injection technique. Patients in Maine who prefer in-person training can ask the prescriber to coordinate a single urology clinic visit for supervised first injection.

Step 5. Receive medication. Retail pharmacies stocking Caverject typically dispense within one to two days. 503A compounding pharmacies generally ship within three to five business days after the prescription is received and verified.

Review FDA guidance on sterile compounding under 503A

503A Compounding Pharmacies and Alprostadil in Maine

A 503A pharmacy is a traditional compounding pharmacy, licensed under state law and subject to United States Pharmacopeia (USP) Chapter 797 sterility standards for sterile preparations. In Maine, 503A pharmacies operate under the Maine Board of Pharmacy's authority and can legally compound alprostadil for injection when a valid patient-specific prescription exists [9].

Compounded alprostadil is often chosen for two reasons. First, brand-name Caverject can be difficult to find at retail pharmacies in rural Maine, where pharmacy deserts are a documented problem; according to the CDC, approximately 22% of Maine's population lives in a rural area [10]. Second, compounded formulations allow the prescriber to write for concentrations and volumes not available commercially, useful for patients whose optimal dose falls between standard Caverject kit sizes.

503A pharmacies cannot compound copies of commercially available products without a documented clinical rationale. Alprostadil compounding is generally accepted because the commercially available concentrations (5 mcg/mL, 10 mcg/mL, 20 mcg/mL, 40 mcg/mL vials) do not cover every titration step a patient may need, and because rural access barriers constitute a legitimate clinical reason [9].

The pharmacy must be licensed in Maine to ship to a Maine patient. Patients should verify licensure via the Maine Board of Pharmacy's online verification tool before sending a prescription to any out-of-state 503A compounder.

Check USP Chapter 797 sterility standards for sterile compounding

Dosing: Caverject Injection vs. MUSE Suppository

Choosing between intracavernosal injection and intraurethral suppository depends on patient dexterity, needle aversion, and efficacy expectations. The two delivery systems carry different dose ranges, onset profiles, and side-effect patterns [1][2][11].

Caverject (intracavernosal injection):

Starting dose for psychogenic or mixed erectile dysfunction: 2.5 mcg. Starting dose for neurogenic erectile dysfunction: 1.25 mcg. Dose is titrated in 2.5 mcg increments under medical supervision until the patient achieves an erection lasting 60 minutes or less. The maximum recommended single dose is 60 mcg, though most patients find their effective dose between 10 mcg and 20 mcg [3]. The injection is given into the lateral aspect of the proximal third of the penis using a 0.5-inch, 27- to 30-gauge needle. Erection onset occurs within 5 to 10 minutes and duration is 30 to 60 minutes. Use is limited to three times per week with at least 24 hours between doses [3].

MUSE (intraurethral suppository):

Available in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg pellets. The prescriber typically starts at 250 mcg and titrates up or down. Onset is 5 to 10 minutes after urethral insertion. Efficacy is modestly lower than injection: a 1997 multicenter trial (N=1,511) published in the New England Journal of Medicine found that 64.9% of home-use attempts with intraurethral alprostadil resulted in successful intercourse in responders, compared with 18.6% in the placebo group [2]. MUSE avoids needle injection but carries a small risk of urethral burning (reported in approximately 36% of patients) and hypotension if the drug is absorbed systemically [2].

Read the MUSE efficacy trial on PubMed

Side Effects, Contraindications, and Safety Monitoring

The most clinically significant adverse event for alprostadil injection is priapism, defined as an erection lasting more than four hours. The incidence of priapism requiring medical intervention in clinical trials was approximately 0.4% with Caverject [3][12]. Patients must be instructed to go to an emergency department immediately if an erection persists beyond four hours, as ischemic priapism causes irreversible corporal fibrosis if not treated promptly [12].

Penile pain at the injection site occurs in approximately 37% of patients using Caverject and is the most common reason for discontinuation [3]. Prolonged erection (60 minutes to four hours) occurs in about 5% of patients during dose titration and can usually be managed with penile cold compression or, in a clinic setting, intracavernosal injection of phenylephrine [12].

Hematoma at the injection site affects roughly 3% of users and typically resolves without intervention [3]. Fibrosis or nodule formation has been reported with long-term use; men using Caverject for more than 12 months should have a penile examination every six months [13].

Absolute contraindications include: known hypersensitivity to alprostadil, conditions predisposing to priapism (sickle cell anemia, sickle cell trait, multiple myeloma, leukemia), anatomical deformity of the penis (Peyronie's disease with significant curvature), and penile implant in place [3][7]. Alprostadil should not be used with other vasoactive agents for erectile dysfunction without explicit prescriber oversight.

Review the AHA cardiovascular risk statement for sexual activity in men with cardiac disease

Prior Authorization for MaineCare (Maine Medicaid) Coverage

MaineCare covers alprostadil for refractory erectile dysfunction with prior authorization. The PA process requires the prescriber to document that the patient meets specific clinical criteria before the state will approve coverage.

Standard PA documentation requirements for MaineCare alprostadil:

A diagnosis of erectile dysfunction using ICD-10 code N52.9 (or a more specific code where applicable), documentation that the patient has had an adequate trial of at least one oral PDE5 inhibitor (sildenafil 50 to 100 mg or tadalafil 10 to 20 mg for at least four attempts) without adequate response or with documented contraindication, a note confirming the absence of priapism risk factors, and the prescriber's NPI number and Maine license number [14].

The PA request is submitted by the prescribing provider, not the patient, through the MaineCare Provider Portal or by fax using the Pharmaceutical and Therapeutics Committee's standard form. Standard review takes up to 72 hours; urgent review takes 24 hours. Approvals are typically granted for 12 months and require renewal documentation at expiration [14].

Patients with private insurance through employers or the ACA marketplace in Maine should verify alprostadil coverage separately. Many commercial plans in Maine cover Caverject under the pharmacy benefit with a prior authorization requirement similar to MaineCare's criteria.

Review Maine DHHS MaineCare pharmacy benefit policy

Transferring an Existing Alprostadil Prescription to Maine

Patients relocating to Maine who already have an active alprostadil prescription from another state face a straightforward but state-specific process. Maine law allows a Maine-licensed pharmacist to fill a prescription originally written by an out-of-state prescriber, provided the prescription is valid and the prescriber holds a license in their original state [15].

Prescription transfers between pharmacies follow the standard DEA rules for non-scheduled drugs: the original pharmacy faxes or electronically transfers the prescription to the Maine pharmacy, and the receiving pharmacist verifies prescriber credentials. Because alprostadil is not a controlled substance, there is no limit on transfer frequency.

If the original prescriber is not licensed in Maine, they cannot continue prescribing for the patient once the patient establishes Maine residency and the original prescription expires. The patient will need to establish care with a Maine-licensed provider, either in person or via telehealth, before the prescription runs out. A new prescriber can request records from the prior provider to document treatment history and avoid repeating the full baseline workup if recent labs (within six months) are available.

Check Maine Board of Pharmacy prescription transfer rules

What to Expect at Your First Alprostadil Injection: A Clinical Walkthrough

The first injection experience follows a predictable arc. Knowing what to expect reduces anxiety and improves technique compliance.

Before the injection: Wash hands thoroughly. Inspect the vial for particulate matter or discoloration. Assemble the Caverject Impulse dual-chamber system or draw the compounded alprostadil into the provided syringe. Confirm the dose is the one the prescriber specified.

Site selection: Choose the lateral aspect of the proximal one-third of the penis, alternating sides with each use. Avoid the dorsal midline (urethra runs there), the ventral midline (dorsal vein), and any visible veins. Retract foreskin if present [3].

Injection: Stabilize the glans with one hand. Insert the needle perpendicularly into the chosen site. Aspirate briefly to confirm no blood return (ruling out intravascular placement). Inject the full dose slowly over 5 to 10 seconds. Withdraw the needle and apply gentle pressure for three to five minutes with a clean cloth.

After the injection: Expect tumescence to begin within 5 to 10 minutes. Walk or stand briefly; mild activity may improve response. If no erection occurs after 15 minutes, do not inject a second dose. Contact the prescriber for dose adjustment guidance at the next visit.

Signs requiring emergency evaluation: An erection lasting more than four hours, significant penile pain not resolving after ejaculation, or any sign of hematoma expanding rapidly. Go directly to an emergency department; do not wait.

See the FDA Caverject prescribing information for injection site instructions

Cost and Pharmacy Access in Maine

Brand-name Caverject Impulse 10 mcg kits retail for approximately $90 to $130 per single-dose dual-chamber kit at Maine retail pharmacies without insurance. A six-dose vial pack of Caverject 20 mcg retails for approximately $350 to $450 without insurance. MUSE suppositories retail for roughly $100 to $140 per six-pellet pack.

Compounded alprostadil from a Maine-licensed 503A pharmacy is generally priced 40% to 60% lower than brand-name Caverject for equivalent doses, making it a meaningful option for patients paying out of pocket. A 5 mL multi-dose vial of compounded alprostadil 20 mcg/mL (providing approximately 20 individual 5 mcg doses) typically costs between $60 and $100 depending on the pharmacy.

Pfizer offers a patient assistance program for Caverject through its RxPathways program for patients who meet income criteria [16]. GoodRx and similar discount platforms apply to brand Caverject at participating Maine pharmacies and can reduce out-of-pocket cost by 20% to 40%.

Rural Maine patients who have difficulty accessing a retail pharmacy stocking Caverject should ask their prescriber to route the prescription to a 503A compounder that ships directly to Maine home addresses. This is the most practical solution for patients in Aroostook, Washington, or Piscataquis counties where pharmacy access is limited.

See the CDC rural health pharmacy access data

Monitoring and Follow-Up After Starting Alprostadil in Maine

Ongoing monitoring keeps treatment safe and effective. The AUA erectile dysfunction guideline recommends a follow-up visit within 30 days of starting intracavernosal therapy, then every six months thereafter for men on long-term treatment [5].

At the 30-day follow-up, the prescriber confirms the patient is using correct injection technique, reviews any adverse events (hematoma, prolonged erection, pain), verifies the dose is producing the desired erectile response, and assesses for early signs of fibrosis. Dose adjustments at this stage are common; approximately 35% of patients starting at 5 mcg require an upward adjustment after the first month of home use [13].

Annual lab review should include testosterone levels in any patient who was borderline hypogonadal at baseline, because testosterone optimization may allow dose reduction or discontinuation of alprostadil in some men [8]. Penile examination for nodules or curvature changes is recommended every six months for men using Caverject for more than one year [13].

Review the endocrine evaluation of male sexual dysfunction